The Role of miR‐21 in Cancer
Abstract
MicroRNAs (miRNAs) are small endogenous noncoding RNAs that suppress gene expression at the post-transcriptional level. In the past decade, miRNAs have been extensively studied in a number of different human cancers. MiRNAs have been identified to act both as oncogenes and as tumor suppressors. In addition, miRNAs are associated with the intrinsic resistance of cancer to various forms of therapy, and they are implicated in both tumor progression and metastasis. The characterization of the specific alterations in the patterns of miRNA expression in cancer has great potential for identifying biomarkers for early cancer detection, as well as for potential therapeutic intervention in cancer treatment. In this chapter, we describe the ever-expanding role of miR-21 and its target genes in different cancers, and provide insight into how this oncogenic miRNA regulates cancer cell proliferation, migration, and apoptosis by suppressing the expression of tumor suppressors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
miR-21 is clearly involved in key regulatory pathways.
“miR-21 is clearly involved in key regulatory pathways.”
From miR-21: a non‐specific biomarker of all maladies (2021) · cites this paper as [26]
The citation lists haven’t been fetched yet
References 74 · Cited by 325
- Authors
- Pfeffer, S. R., Yang, C. H., & Pfeffer, L. M.
- Affiliations
- University of Tennessee Health Science Center (US)
- Corresponding author
- Pfeffer, Lawrence M.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 2015-06-16
- Volume
- 76
- Issue
- 6
- Pages
- 270-277
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2138930960
- Cited by
- 325
- References
- 74
- Citations by year
- 2026: 11 · 2025: 22 · 2024: 22 · 2023: 40 · 2022: 34 · 2021: 36 · 2020: 45 · 2019: 53 · 2018: 37 · 2017: 19 · 2016: 3 · 2015: 3
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Development Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Health (CA133322)
- Department of Defense (W81XWH-11-1-0533)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- miR-21, microRNA, oncogenic microRNA, tumor suppressor, post-transcriptional regulation, tumor cell proliferation, cell migration, apoptosis, metastasis, tumor progression, chemoresistance, tumor markers, therapeutic target
- MeSH terms
- Animals, Cell Survival, Humans, Neoplasms, Protein-Arginine N-Methyltransferases, Signal Transduction, Cytokines, Insulin-Like Growth Factor Binding Protein 3, MicroRNAs, F-Box Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
